Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.: Where Does Claim Construction Go From Here?
1min
Dominick Conde analyzes the Supreme Court’s January 20th, 2015 decision in Teva Pharmaceuticals v. Sandoz, which overturned the Federal Circuit’s de novo standard of review for district court claim constructions, and its implications on future patent litigations.
IAM Patent 1000 Continues to Recognize Venable’s IP Practice and Attorneys Among the Leaders in California, the DC Metro Area, Illinois, and New York for 2022